Table 4.
Treatment | IC50 (mg/mL) |
Maximum Activity * (%) |
---|---|---|
Control | 10.04 ± 0.45 a | 69.07 ± 2.04 d |
100 °C, 1 h | 10.17 ± 0.64 a | 70.73 ± 3.45 d |
100 °C, 2 h | 9.33 ± 0.07 ab | 72.02 ± 2.56 cd |
100 °C, 3 h | 9.13 ± 0.39 ab | 74.28 ± 2.64 cd |
100 °C, 4 h | 8.71 ± 0.39 b | 72.92 ± 0.87 bcd |
121 °C, 1 h | 7.09 ± 0.14 c | 77.42 ± 1.87 bc |
121 °C, 2 h | 6.15 ± 0.33 cd | 80.65 ± 2.17 b |
121 °C, 3 h | 5.72 ± 0.36 d | 89.16 ± 2.52 a |
121 °C, 4 h | 5.85 ± 0.33 d | 90.63 ± 0.56 a |
* Maximum activity of all WSCGDs was determined at the same concentration of 20 mg/mL. ND: not detected. The letters a, b, c, d, e in the same column represent the statistical difference of means with p < 0.05 using the Tukey-test. All data points in the table are mean and standard deviation. The anti-α-glucosidase activity of the WSC and WSCGDs were conducted at 20 °C for 20 min.